



PD-L1 IHC 22C3 pharmDx Assay

— e-learning course



Are you ready to be a part of the paradigm shift in cancer treatment from conventional chemotherapy to targeted therapy for improved outcomes in cancer patients?

If you are keen to master the novel companion diagnostic assays to help cancer patients choose the right targeted therapy, **PD-L1 IHC 22C3 pharmDx Assay e-learning course is the right stop!**

The course has been developed to enhance your understanding of PD-L1 testing and PD-L1 IHC 22C3 pharmDx assay and provide guidance to the use of targeted PD-1/PD-L1 checkpoint inhibitors in certain cancers. The three modules and topics covered in this e-learning course are listed below.



PD-L1 testing

- PD-1/ PD-L1 checkpoint inhibitors
- Importance of PD-L1 testing
- Implications of using LDTs versus IVDs
- Importance of personalised medicine & CDx

PD-L1 IHC 22C3 pharmDx assay

- Assay overview
- Scoring guidelines (TPS & CPS)
- Approved indications
- Platforms (SK006 & GE006)
- Assay validation



Education & training resources

- Guidance on online education & training resources for interpreting assay results
- External quality assurance programs for PD-L1 testing

Click here to

ENROL TODAY

OR

Scan QR code



(PD-L1: Programmed death-ligand 1, IHC: Immunohistochemistry; LDT: Laboratory developed tests, IVD: *In vitro* diagnostic; TPS: Tumor proportion score; CPS: Combined positive score; CDx: companion diagnostic).

This message has been sent to you because you are a healthcare professional. This is a system generated email. Please do not reply to it. The content of this email is confidential and intended for the recipient specified in message only. It is strictly forbidden to share any part of this message with any third party, without a written consent of the sender. If you received this message by mistake, please contact your local representative so that we can ensure such a mistake does not occur in the future.

Organised by:



Supported by:

